样式: 排序: IF: - GO 导出 标记为已读
-
Patenting perspective of modulators of ClpP endopeptidase: 2019-present Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-09-16 Zhenyu Wang, Liqing He, Ziheng Fan, Youfu Luo
ClpP is a highly conserved serine protease that plays a crucial role in maintaining protein homeostasis in both bacterial cells and human mitochondria. Several studies have demonstrated the potenti...
-
MEK inhibitors in oncology: a patent review and update (2016 - present) Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-09-14 Anjali Suryavanshi, Vandana, Yugal Kishor Shukla, Vipul Kumar, Pragya Gupta, Vivek Asati, Debarshi Kar Mahapatra, Raj K. Keservani, Sanmati Kumar Jain, Sanjay Kumar Bharti
Mitogen-activated protein kinase (MEK) is one of the important components of Ras/Raf/MEK/ERK signaling pathway, transduces signal for cell growth, differentiation, and development. Deregulation of ...
-
Trends in covalent drug discovery: a 2020–23 patent landscape analysis focused on select covalent reacting groups (CRGs) found in FDA-approved drugs Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-09-11 Jan Felix Scholtes, Cristobal Alhambra, Philip A. Carpino
Covalent drugs contain electrophilic groups that can react with nucleophilic amino acids located in the active sites of proteins, particularly enzymes. Recently, there has been considerable interes...
-
Helicase-primase inhibitors for the treatment of herpes simplex virus infections – patent evaluation of WO2023/225162 from gilead sciences inc Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-09-11 Christian Gege, Gerald Kleymann
Helicase-primase is an interesting target for small molecule therapy of herpes simplex virus (HSV) infections. With amenamevir already approved for varicella-zoster virus and herpes simplex in Japa...
-
Ephrin receptor type-A2 (EphA2) targeting in cancer: a patent review (2018-present). Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-09-11 Massimiliano Tognolini,Francesca Romana Ferrari,Alfonso Zappia,Carmine Giorgio
INTRODUCTION EphA2 is a tyrosine kinase receptor and is considered a promising target in cancer. Different approaches are used to target EphA2 receptor, and a lot of preclinical data demonstrate the potential exploitation of this receptor in clinical oncology for diagnosis and cancer therapy, including immunotherapy. AREAS COVERED In this review, we have summarized the recent patents involving the
-
Update on JNK inhibitor patents: 2015 to present. Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-09-08 Guotai Feng,Xiao Yang,Wen Shuai,Guan Wang,Liang Ouyang
INTRODUCTION c-Jun N-terminal kinase (JNK) regulates various biological processes through the phosphorylation cascade and is closely associated with numerous diseases, including inflammation, cardiovascular diseases, and neurological disorders. Therefore, JNKs have emerged as potential targets for disease treatment. AREAS COVERED This review compiles the patents and literatures concerning JNK inhibitors
-
An updated patent review of BRD4 degraders. Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-09-04 Zonghui Ma,Cun Zhang,Andrew A Bolinger,Jia Zhou
INTRODUCTION Bromodomain-containing protein 4 (BRD4), an important epigenetic reader, is closely associated with the pathogenesis and development of many diseases, including various cancers, inflammation, and infectious diseases. Targeting BRD4 inhibition or protein elimination with small molecules represents a promising therapeutic strategy, particularly for cancer therapy. AREAS COVERED The recent
-
Caspase inhibitors: a review on recently patented compounds (2016–2023) Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-08-29 Shivani Kasana, Shivam Kumar, Preeti Patel, Balak Das Kurmi, Shweta Jain, Sanjeev Sahu, Ankur Vaidya
Caspases are a family of protease enzymes that play a crucial role in apoptosis. Dysregulation of caspase activity has been implicated in various pathological conditions, making caspases an importa...
-
Tetrahydroisoquinolines – an updated patent review for cancer treatment (2016 – present) Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-08-10 Ankur Kumar Tanwar, Neha Sengar, Nobuyuki Mase, Inder Pal Singh
Cancer is a prominent cause of death globally, triggered by both non-genetic and genetic alterations in genes influenced by various environmental factors. The tetrahydroisoquinoline (THIQ), specifi...
-
A patent review of histone deacetylase 8 (HDAC8) inhibitors (2013-present) Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-08-09 Suvankar Banerjee, Balaram Ghosh, Tarun Jha, Nilanjan Adhikari
The processes and course of several fatal illnesses, such as cancer, inflammatory diseases, and neurological disorders, are closely correlated with HDAC8. Therefore, novel HDAC8 inhibitors represen...
-
SGLT2 inhibitors for the treatment of diabetes: a patent review (2019–23) Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-08-02 Rahul Baghel, Nikita Chhikara, Pawan Kumar, Akhilesh Kumar Tamrakar
The sodium-glucose co-transporter 2 (SGLT2) inhibitors are FDA-approved class of drugs for diabetes management. They improve glycemic control by inducing glucosuria. Notwithstanding with potent ant...
-
Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson’s disease: a patent review of the literature to date Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-07-19 Margaux Morez, Antonio Jesús Lara Ordóñez, Patricia Melnyk, Maxime Liberelle, Nicolas Lebègue, Jean-Marc Taymans
Nearly two decades after leucine rich repeat kinase 2 (LRRK2) was discovered as a genetic determinant of Parkinson’s disease (PD), LRRK2 has emerged a priority therapeutic target in PD and inhibiti...
-
A patent review of small molecule CDK4/6 inhibitors in the treatment of cancer: 2020–present Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-07-17 Xiaoling Huang, Shidi Xu, Lei Duan, Shan Xu, Wufu Zhu
Cyclin-dependent protein kinase 4/6 (CDK4/6) is a class of serine/threonine protein kinases that plays a key role in the regulation of the cell cycle. CDK4/6 is highly expressed in cancers such as ...
-
Progress with polo-like kinase (PLK) inhibitors: a patent review (2018–present) Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-07-15 Shirong Bian, Ru Zhang, Jianyu Nie, Mingxing Zhu, Zhouling Xie, Chenzhong Liao, Qin Wang
Polo-like kinases (PLKs) have five isoforms, all of which play crucial roles in cell cycle and cell proliferation, offering opportunities for drug design and treatment of cancers and other related ...
-
The therapeutic potential of phosphodiesterase 9 (PDE9) inhibitors: a patent review (2018-present) Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-07-09 Chen Zhang, Zhao-Hang Xue, Wei-Hao Luo, Mei-Yan Jiang, Yinuo Wu
Phosphodiesterase 9 (PDE9) has been demonstrated as a potential target for neurological disorders and cardiovascular diseases, such as Alzheimer’s disease and heart failure. For the last few years,...
-
Therapeutic potential of boswellic acids: an update patent review (2016–2023) Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-07-05 Hidayat Hussain, Daijie Wang, Hesham R. El-Seedi, Luay Rashan, Ishtiaq Ahmed, Muzaffar Abbas, Nilufar Z. Mamadalieva, Haider N. Sultani, Muhammad Iftikhar Hussain, Syed Tasadaque A. Shah
Boswellic acids (BAs) are a group of pentacyclic triterpenoids of the ursane and oleanane type. They have shown very interesting biological properties that have led to the development of a number o...
-
Selective COX-2 inhibitors as anticancer agents: a patent review (2018-2023) Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-07-03 Mohammad Mahboubi-Rabbani, Amir Hossein Abdolghaffari, Mahsa Ghesmati, Ali Amini, Afshin Zarghi
COX-2 is a crucial enzyme in the manufacture of prostaglandins. The enzyme’s metabolites might have an important function as regulators of the inflammatory response and other medical conditions suc...
-
FAK inhibitors in cancer, a patent review – an update on progress Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-07-02 Ya-Xi Ye, Yu-Yao Cao, Li-Sheng Xu, Hai-Chao Wang, Xin-Hua Liu, Hai-Liang Zhu
Focal adhesion kinase (FAK) is a cytoplasmic non-receptor tyrosine kinase over-expressed in various malignancies which is related to various cellular functions such as adhesion, metastasis and prol...
-
Patent review of cannabinoid receptor type 2 (CB2R) modulators (2016-present) Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-07-02 Miroslav Kosar, Leonard Mach, Erick M. Carreira, Marc Nazaré, Pal Pacher, Uwe Grether
Cannabinoid receptor type 2 (CB2R), predominantly expressed in immune tissues, is believed to play a crucial role within the body’s protective mechanisms. Its modulation holds immense therapeutic p...
-
Inhibition of GTPase KRASG12D: a review of patent literature Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-06-26 Yuhang Li, Le Yang, Xiaoran Li, Xiaojin Zhang
KRAS is a critical oncogenic protein intricately involved in tumor progression, and the difficulty in targeting KRAS has led it to be classified as an ‘undruggable target.’ Among the various KRAS m...
-
An updated patent review on PD-1/PD-L1 antagonists (2022-present) Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-06-25 Wiktor Uzar, Beata Kaminska, Hubert Rybka, Lukasz Skalniak, Katarzyna Magiera-Mularz, Radoslaw Kitel
PD-L1, via its interactions with PD-1, constitutes a key immune checkpoint that allows cancer cells to escape immune surveillance. Targeting PD-1/PD-L1 with monoclonal antibodies (mAbs) led to spec...
-
Protein tyrosine phosphatase inhibitors: a patent review and update (2012–2023) Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-06-19 Lakshmi Mounika Kelam, Vaishnavi Chhabra, Sarika Dhiman, Deevena Kumari, M. Elizabeth Sobhia
Protein tyrosine phosphatases (PTPs), essential and evolutionarily highly conserved enzymes, govern cellular functions by modulating tyrosine phosphorylation, a pivotal post-translational modificat...
-
Recent advances in the development of P2Y14R inhibitors: a patent and literature review (2018-present) Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-06-19 Kai Wang, Fen Zhong, Zhou-Dong Zhang, Huan-Qiu Li, Sheng Tian
The P2Y14 receptor (P2Y14R), a member of the G protein-coupled receptor family, is activated by extracellular nucleotides. Due to its involvement in inflammatory, immunological and other associated...
-
A patent review on hypoxia-inducible factor (HIF) modulators (2021–2023) Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-06-19 Jiaming Liu, Yinli Gao, Xiaojin Zhang
Hypoxia-inducible factor (HIF) is a central regulatory factor in detecting and adapting to cellular oxygen stress. Dysregulation of HIF is associated with various human diseases. Seven HIF modulato...
-
An updated patent review of stimulator of interferon genes agonists (2021 – present) Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-06-13 Guo-Feng Xin, Nan-Nan Chen, Lin-Lin Li, Xue-Chun Liu, Chun-Chen Che, Bei-Duo Wu, Qi-Dong You, Xiao-Li Xu
Stimulator of Interferon Genes (STING) is an innate immune sensor. Activation of STING triggers a downstream response that results in the expression of proinflammatory cytokines (TNF-α, IL-1β) via ...
-
HDAC3 inhibitors: a patent review of their broad-spectrum applications as therapeutic agents Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-06-14 Thabo Brighton Makgoba, Erika Kapp, Samuel Egieyeh, Jacques Joubert
Histone deacetylases (HDACs) are a class of zinc-dependent enzymes. They maintain acetylation homeostasis, with numerous biological functions and are associated with many diseases. HDAC3 strictly r...
-
Fighting antibacterial drug resistance Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-06-12 Claudiu T. Supuran
Published in Expert Opinion on Therapeutic Patents (Just accepted, 2024)
-
Management of Neisseria gonorrhoeae infection: from drug resistance to drug repurposing Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-06-10 Luigi Pisano, Simone Giovannuzzi, Claudiu T. Supuran
Neisseria gonorrhoeae is a common sexually transmitted disease connected with extensive drug resistance to many antibiotics. Presently, only expanded spectrum cephalosporins (ceftriaxone and cefixi...
-
PIM kinase inhibitors: an updated patent review (2016-present) Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-06-13 Anushka Sharma, Rahul Dubey, Shankar Gupta, Vivek Asati, Vipul Kumar, Dileep Kumar, Debarshi Kar Mahapatra, Meenakshi Jaiswal, Sanmati Kumar Jain, Sanjay Kumar Bharti
PIM Kinases (PIM-1, PIM-2, and PIM-3) have been reported to play crucial role in signaling cascades that govern cell survival, proliferation, and differentiation. Over-expression of these kinases l...
-
A patent review of SHP2 allosteric inhibitors (2018-present) Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-06-13 Alessia Petrocchi, Alina Ciammaichella
SHP2 (Src homology region 2-containing protein tyrosine phosphatase 2) is a target of interest for cancer therapy due to its key role in the regulation of the RAS/MAPK signal transduction pathway d...
-
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-06-11 Massimiliano Gasparrini, Simone Giovannuzzi, Alessio Nocentini, Nadia Raffaelli, Claudiu T. Supuran
Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme in the biosynthesis of nicotinamide adenine dinucleotide (NAD) from nicotinamide. In addition to its role as essential red...
-
Biomedical applications of prokaryotic carbonic anhydrases: an update Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-06-11 Clemente Capasso, Claudiu T. Supuran
This review offers an updated perspective on the biomedical applications of prokaryotic carbonic anhydrases (CAs), emphasizing their potential as targets for drug development against antibiotic-res...
-
An updated patent review of TRPA1 antagonists (2020 – present) Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-06-07 Rosa Maria Vitale, Luciano de Petrocellis, Pietro Amodeo
TRPA1 is a nonselective calcium channel, member of the transient receptor potential (TRP) superfamily, also referred to as the ‘irritant’ receptor, being activated by pungent and noxious exogenous ...
-
Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (July 2021 - December 2023) Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-06-05 James S. Scott, Teresa C. M. Klinowska
Breast cancer is the most frequently diagnosed cancer worldwide. With around 70% of breast cancers expressing the estrogen receptor (ER), molecules capable of antagonizing and degrading ER (SERDs) ...
-
A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018 – present) Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-06-03 Jamshed Iqbal, Sehrish Bano, Imtiaz Ali Khan, Qing Huang
The purinergic P2×7receptor is expressed on the surface of many different types of cells, including immune cells. Targeting P2×7receptors with antagonists has been studied for its potential therape...
-
Type II & III inhibitors of tropomyosin receptor kinase (Trk): a 2020–2022 patent update Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-05-24 Petar Iliev, Carolin Jaworski, Carmen Wängler, Björn Wängler, Brent D.G. Page, Ralf Schirrmacher, Justin J. Bailey
The Trk family proteins are membrane-bound kinases predominantly expressed in neuronal tissues. Activated by neurotrophins, they regulate critical cellular processes through downstream signaling pa...
-
Kinase inhibitors: 20 years of success and many new challenges and recent trends in their patents Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-05-24 Mourad A. M. Aboul-Soud, Yazeed A. Al-Sheikh, Hazem K. Ghneim, Claudiu T. Supuran, Fabrizio Carta
Protein kinases (PKs) play key roles in cellular signaling and regulation cascades and therefore are listed among the most investigated enzymes with the intent to develop drugs that are able to mod...
-
Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors – a review of patent literature from 2019–June 2023 Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-05-20 Esther C. Y. Lee, Kyle D. Reichl, Ariamala Gopalsamy
SMARCA2 and SMARCA4 are subunits of the SWI/SNF complex which is a chromatin remodeling complex and a key epigenetic regulator that facilitates gene expression. Tumors with loss of function mutatio...
-
An insight into the last 5-year patents on Porphyromonas gingivalis and Streptococcus mutans, the pivotal pathogens in the oral cavity Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-05-20 Bianca Laura Bernardoni, Ilaria D’Agostino, Concettina La Motta, Andrea Angeli
The oral cavity harbors an extensive array of over 700 microorganisms, forming the most complex biome of the entire human body, with bacterial species being the most abundant. Oral diseases, e.g. p...
-
Anticancer drugs: where are we now? Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-05-15 Giuseppina De Simone, Claudiu T. Supuran
Published in Expert Opinion on Therapeutic Patents (Vol. 34, No. 7, 2024)
-
Recent trends and challenges to overcome Pseudomonas aeruginosa infections Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-05-03 Alessandra Ammazzalorso, Arianna Granese, Barbara De Filippis
Pseudomonas aeruginosa (PA) is a Gram-negative bacterium that can cause a wide range of severe infections in immunocompromised patients. The most difficult challenge is due to its ability to rapidl...
-
Targeting the TGF-β signaling pathway: an updated patent review (2021–present) Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-04-25 Wenhao Guo, Hanwen Liu, Yong Yan, Di Wu, Hequan Yao, Kejiang Lin, Xuanyi Li
The TGF-β signaling pathway is a complex network that plays a crucial role in regulating essential biological functions and is implicated in the onset and progression of multiple diseases. This rev...
-
PCSK9 inhibitors: a patent review 2018-2023 Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-04-08 Enrico Mario Alessandro Fassi, Andrea Citarella, Marco Albani, Erica Ginevra Milano, Laura Legnani, Carmen Lammi, Alessandra Silvani, Giovanni Grazioso
Published in Expert Opinion on Therapeutic Patents (Just accepted, 2024)
-
Targeting the PI3K/AKT signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023) Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-04-09 Dima A. Sabbah, Rima Hajjo, Sanaa K. Bardaweel, Haizhen A. Zhong
Recent years have witnessed great achievements in drug design and development targeting the phosphatidylinositol 3-kinase/protein kinase-B (PI3K/AKT) signaling pathway, a pathway central to cell gr...
-
A patent review on HMGB1 inhibitors for the treatment of liver diseases Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-04-09 Richa Raj, Pingping Shen, Boyang Yu, Jian Zhang
HMGB1 is a non-histone chromatin protein released or secreted in response to tissue damage or infection. Extracellular HMGB1, as a crucial immunomodulatory factor, binds with several different rece...
-
Biofilm and bacterial membrane vesicles: recent advances Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-04-05 Valentina Puca, Beatrice Marinacci, Benedetta Pellegrini, Floriana Campanile, Maria Santagati, Rossella Grande
Bacterial Membrane Vesicles (MVs) play important roles in cell-to-cell communication and transport of several molecules. Such structures are essential components of Extracellular Polymeric Substanc...
-
An overview on recent patents and technologies on nanoparticles for nucleic acid delivery Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-04-08 Larissa Moraes dos Santos Fonseca, Bruna Aparecida Souza Machado, Fabricia Oliveira Oliveira, Jânio Rodrigo de Jesus Santos, Jaqueline Wang da Silva, Katharine Valeria Saraiva Hodel, Brisa Gonçalves Rosatti, Claudio Damasceno Pinto, Milena Botelho Pereira Soares
Nucleic acid-based therapeutics offer groundbreaking potential for treating genetic diseases and advancing next-generation vaccines. Despite their promise, challenges in efficient delivery persist ...
-
Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors – a review of patent literature from 2019–30 June 2023 Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-04-05 Kyle D. Reichl, Esther C. Y. Lee, Ariamala Gopalsamy
The multi-subunit SWI/SNF chromatin remodeling complex is a key epigenetic regulator for many cellular processes, and several subunits are found to be mutated in human cancers. The inactivating mut...
-
Targeting the relaxin-3/RXFP3 system: a patent review for the last two decades Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-04-04 Md Toufiqur Rahman, Hetti Handi Chaminda Lakmal, Javeena Hussain, Chunyang Jin
The neuropeptide relaxin-3/RXFP3 system belongs to the relaxin/insulin superfamily and is involved in many important physiological processes, such as stress responses, appetite control, and motivat...
-
Carbonic anhydrase and bacterial metabolism: a chance for antibacterial drug discovery Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-03-20 Clemente Capasso, Claudiu T. Supuran
Carbonic anhydrases (CAs, EC 4.2.1.1) play a pivotal role in the regulation of carbon dioxide , bicarbonate, and hydrogen ions within bacterial cells, ensuring pH homeostasis and facilitating energ...
-
Peroxisome Proliferator-Activated Receptor agonists and antagonists: an updated patent review (2020–2023) Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-03-20 Barbara De Filippis, Arianna Granese, Alessandra Ammazzalorso
The search for novel compounds targeting Peroxisome Proliferator-Activated Receptors (PPARs) is currently ongoing, starting from the previous successfully identification of selective, dual or pan a...
-
Therapeutic cysteine protease inhibitors: a patent review (2018–present) Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-03-14 Giulia Barchielli, Antonella Capperucci, Damiano Tanini
Cysteine proteases are involved in a broad range of biological functions, ranging from extracellular matrix turnover to immunity. Playing an important role in the onset and progression of several d...
-
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023) Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-03-12 Rima Hajjo, Dima A. Sabbah, Sanaa K. Bardaweel, Haizhen A. Zhong
Recent years have seen significant strides in drug developmenttargeting the EGFR/RAS/RAF signaling pathway which is critical forcell growth and proliferation. Protein-protein interaction networksam...
-
Recent developments of agents targeting vibrio cholerae: patents and literature data Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-03-06 Francesco Melfi, Simone Carradori, Noemi Mencarelli, Cristina Campestre, Arianna Granese, Mattia Mori
Vibrio cholerae bacteria cause an infection characterized by acute diarrheal illness in the intestine. Cholera is sustained by people swallowing contaminated food or water. Even though symptoms can...
-
Recent developments of HSP90 inhibitors: an updated patent review (2020-present) Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-03-08 Jianfeng Liu, Huangliang Shu, Qinxin Xia, Qidong You, Lei Wang
The 90-kDa heat shock protein (HSP90) functions as a molecular chaperone, it assumes a significant role in diseases such as cancer, inflammation, neurodegeneration, and infection. Therefore, the re...
-
Successes and challenges in the development of BD1-selective BET inhibitors: a patent review Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-03-05 Monica Viviano, Alessandra Cipriano, Emanuele Fabbrizi, Alessandra Feoli, Sabrina Castellano, Gianluca Sbardella, Antonello Mai, Ciro Milite, Dante Rotili
Bromodomain and ExtraTerminal (BET) domain proteins are transcriptional cofactors that, recognizing acetylated lysines of histone and non-histone proteins, can modulate gene expression. BET family ...
-
Photodynamic therapy alone or in combination to counteract bacterial infections Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-03-04 Sébastien Clément, Jean-Yves Winum
Antibacterial photodynamic therapy presents a promising alternative to antibiotics, with potential against multidrug-resistant bacteria, offering broad-spectrum action, reduced resistance risk, and...
-
Patented farnesoid X receptor modulators: a review (2019 – present) Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-02-03 Antimo Gioiello, Emiliano Rosatelli, Bruno Cerra
The Farnesoid X receptor (FXR) is a key transcription factor that is involved in the bile acid signaling network. The modulation of the FXR activity influences glucose and lipid homeostasis, reduce...
-
The patent review of the biological activity of tropane containing compounds Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-01-15 Thoraya A. Farghaly, Ghada S. Masaret, Hanan Gaber Abdulwahab
Tropane-derived medications have historically played a substantial role in pharmacotherapy. Both natural and synthetic derivatives of tropane find application in addressing diverse medical conditio...
-
Therapeutic applications of thymosin peptides: a patent landscape 2018-present Expert Opin. Ther. Pat. (IF 5.4) Pub Date : 2024-01-15 Michael Quagliata, Anna Maria Papini, Paolo Rovero
Thymosins are small proteins found mainly in the thymus. They are involved in several biological processes, including immunoregulation, angiogenesis, and anti-inflammatory activity. Due to these mu...